ArticleDermatology and therapy2022

Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA.

Dominic Pilon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.